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Background: Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of
hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality.
Methods: Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind,
placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with
polyneuropathy. Eligible patients are 18–85 years old with hATTR amyloidosis, investigator-estimated survival of
≥2 years, Neuropathy Impairment Score (NIS) of 5–130, and polyneuropathy disability score ≤IIIb. Patients are
randomized 2:1 to receive either intravenous patisiran 0.3 mg/kg or placebo once every 3 weeks. The primary objective
is to determine the efficacy of patisiran at 18 months based on the difference in the change in modified NIS+7 (a
composite measure of motor strength, sensation, reflexes, nerve conduction, and autonomic function) between the
patisiran and placebo groups. Secondary objectives are to evaluate the effect of patisiran on Norfolk-Diabetic
Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor
function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the
Composite Autonomic Symptom Score-31 questionnaire). Exploratory objectives include assessment of cardiac function
and pathologic evaluation to assess nerve fiber innervation and amyloid burden. Safety of patisiran will be assessed
throughout the study.
Discussion: APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with
endpoints that capture the multisystemic nature of this disease.
Trial registration: This trial is registered at clinicaltrials.gov (NCT01960348); October 9, 2013.
Keywords: Patisiran, APOLLO, RNA interference, hATTR amyloidosis, mNIS+7, Methods, PolyneuropathyBackground
Hereditary ATTR (hATTR) amyloidosis, formerly known
as familial amyloid polyneuropathy (FAP), is a progres-
sive, life-threatening disease caused by misfolded
transthyretin (TTR) protein that accumulates as amyloid
fibrils in multiple organs, including the nerves, heart,
and gastrointestinal tract [1, 2]. hATTR amyloidosis is a
multisystemic disease with a heterogeneous clinical* Correspondence: david.adams@aphp.fr; adams.david@neuf.fr
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cardiac symptoms that are often concurrent [3–6]. The
unrelenting disease course begins with unimpaired
ambulation (FAP stage 1 [7]), then requirement for as-
sistance with ambulation (FAP stage 2), which proceeds
to wheelchair confinement (FAP stage 3), with patients
experiencing a range of life-impacting symptoms that in-
clude burning neuropathic pain, loss of sensation in
hands and feet, diarrhea/constipation, sexual impotence,
and dizziness/fainting [8–10]. The median survival forle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Adams et al. BMC Neurology  (2017) 17:181 Page 2 of 12patients with hATTR amyloidosis with polyneuropathy
is reported as 5–15 years from diagnosis [9, 11–13].
To date >120 TTR mutations have been reported [14];
some mutations are more strongly associated with poly-
neuropathy (e.g. V30M [8]), and others with cardiomyop-
athy (e.g. V122I [15]). However, this genotype–phenotype
association likely represents an over-simplification, with
wide variation in presentation reported between genotypes
and a mixed phenotype commonly observed [3, 16].
Effectively quantifying the disease burden in hATTR
amyloidosis remains challenging, as there is no single
test that captures the constellation of symptoms and the
multisystemic nature of the condition. Indeed, even as-
sessment of all signs and symptoms of polyneuropathy
requires numerous measures, which recent data suggest
are not adequately captured in current tests [17]. For ex-
ample, the Neuropathy Impairment Score (NIS)-Lower
Limb (NIS-LL) is based on examination of lower limbs
only, so dysfunction occurring in other areas as the dis-
ease progresses cannot be captured. The widely used
NIS overcomes this limitation through clinical examin-
ation of lower limbs, upper limbs, and cranial nerves, al-
though this tool does not include nerve conduction
scores, which are critical to assess the axonal neuropathy
which progresses during the disease course [6, 8, 12]. In
addition, the NIS does not adequately address sensory
loss over the body, which is a hallmark of the disease
[18]. Ultimately, scoring the full range of neuropathic
impairment likely requires a combined measure of the
type, severity, and distribution of neurologic signs and
symptoms [17]. There is also a limited set of tools that
have demonstrated utility in assessment of quality of life
(QoL) and physical functioning in hATTR amyloidosis,
primarily the Norfolk Quality of Life-Diabetic Neur-
opathy (QOL-DN), EuroQoL 5-Dimensions (EQ-5D™),
and Short-Form 36 (SF-36) Health Survey questionnaires
[19–24]. Consequently, the need remains for clinical
trials that include a comprehensive set of measures to
investigate disease progression and the effects of treat-
ment on patient well-being and function.
As TTR is produced predominantly in the liver [25, 26]
orthotopic liver transplantation (OLT) is a well-
recognized and effective treatment strategy for replacing
mutant TTR protein [27, 28]. However, OLT is only
recommended for patients with early-stage hATTR amyl-
oidosis, and survival varies according to modified body
mass index (mBMI), disease duration/severity, and TTR
mutation [8, 28, 29]. The procedure itself is also limited
by issues such as cost, donor availability, cardiac involve-
ment, and toxicities associated with immunosuppression
[2, 30]. Furthermore, disease progression can continue
after OLT as a result of amyloid fibril deposition from
wild-type TTR [31, 32]. More recently, the pharmacother-
apies tafamidis and diflunisal, which stabilize the TTRcomplex and prevent protein misfolding (TTR tetramer
stabilizers), have been utilized. Tafamidis was approved in
Europe for patients with hATTR amyloidosis with early-
stage neurologic disease (FAP stage 1), despite limited
data, with authorization under “exceptional circum-
stances” due to the clinical unmet need [33]. Subsequent
approvals for treatment of symptomatic polyneuropathy
have followed in regions of Latin America and Asia. Diflu-
nisal, a non-steroidal anti-inflammatory drug, has been
used off label for management of hATTR amyloidosis
[34]. In clinical studies, both compounds have slowed pro-
gression of neurologic impairment and were generally well
tolerated [19, 24, 35]. However, progression of neuropathy
symptoms or disability is still observed in some patients
[24, 35–37], and tafamidis may have reduced efficacy in
patients with more severe disease [38]. Thus, there re-
mains a need for novel treatment options for hATTR
amyloidosis.
Patisiran is an investigational RNA interference (RNAi)
therapeutic in clinical development for hATTR amyloid-
osis. Patisiran is a small interfering RNA (siRNA) that tar-
gets a sequence of mRNA conserved across wild-type and
all TTR variants and can thereby reduce serum levels of
both wild-type and pathogenic (mutated) protein [39]. It
is formulated as lipid nanoparticles which direct it to the
liver, the primary source of circulating TTR [39]. The
benefits of lowering mutant TTR levels in patients
with hATTR amyloidosis have been demonstrated by
OLT [40, 41], and data from other amyloidoses show
that clinical outcomes can be improved by reducing
amyloidogenic protein [42–44]. In a Phase 2 study
(NCT01617967) of 29 patients with hATTR amyloid-
osis, two doses of patisiran 0.3 mg/kg every 3 weeks
reduced mean serum TTR levels by approximately
80% [45]. This potent TTR knockdown was observed
for both wild-type and mutant (V30M) forms of TTR,
and in patients who were concurrently receiving TTR
tetramer stabilizers [45]. An ongoing open-label ex-
tension study (NCT01961921) has provided encour-
aging data, with stable measures of neuropathy
impairment and patisiran being generally well toler-
ated through 24 months of treatment [46].
Collectively, these data support the hypothesis that TTR
reduction has the potential to stabilize the progression of
– or even reverse – neuropathy in patients with hATTR
amyloidosis. To date, APOLLO is the largest Phase 3 clin-
ical study in patients with hATTR amyloidosis, designed
to assess the safety and efficacy of patisiran on neurologic
function and QoL.
Methods
Study oversight
This study is conducted according to the guidelines of
the International Conference on Harmonisation, the
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and the Health Insurance Portability and Accountability
Act of 1996. Written informed consent is obtained
from all patients who participate in the study, prior to
assessment of eligibility. The study protocol was ap-
proved by the local Institutional Review Boards and Ethics
Committees, and all subsequent protocol amendments
underwent the same approval procedure. A clinical moni-
tor, as a representative of Alnylam, will follow the study
through periodic site visits and frequent telephone/written
contact. A Data Monitoring Committee will be imple-
mented for the study and provide independent evaluation
to ensure patient safety. This trial is registered at www.cli-
nicaltrials.gov (NCT01960348).Study overview and setting
APOLLO is a randomized, multicenter, international,
double-blind, placebo-controlled, Phase 3 study designed
to evaluate the efficacy of patisiran and establish the
safety of chronic dosing in adult patients with symptom-
atic hATTR amyloidosis with polyneuropathy. A study
schematic is shown in Fig. 1. Patients are recruited from
46 sites across 19 countries (United States, France,
Taiwan, Spain, Japan, Germany, Mexico, Portugal, South
Korea, Sweden, Bulgaria, Italy, Canada, Turkey, Cyprus,
Brazil, Netherlands, United Kingdom, and Argentina).
All but two of the sites are academic hospitals.Informed consent and confirmation of eligibility 
(including tests for NIS and NCSa)
Day -42
to Day 0
Day 0
Day 0
to
Day 560
Randomization (2:1) to patisiran or placebo (double-blind)
9-month efficacy assessments
Rapid disease progression?
( 24-point increase in mNIS+7 and FAP stage progression relative to baseline)
Continue treatment
Decision: 
Continue treatment
Decision: 
Discontinue 
treatment
Continue on study Withdraw from
the study(modified schedule)
18-month efficacy assessments (end of study)b
Double-blind dosing every 3 weeks
NO YES
Screen for open-label extension
Double-blind dosing every 3 weeks
Fig. 1 APOLLO study schematic. aKarnofsky performance status, New
York Heart Association class, safety, and TTR genotyping also assessed
as part of eligibility criteria. b18-month efficacy assessments: mNIS+7,
NIS+7, FAP score, polyneuropathy disability stage, nerve fiber density,
dermal amyloid burden, modified body mass index, timed 10-m walk
test, grip strength test, Composite Autonomic Symptom Score-31
questionnaire, Norfolk Quality of Life-Diabetic Neuropathy questionnaire,
EuroQol 5-Dimensions questionnaire, Rasch-built Overall Disability Scale,
echocardiogram, and cardiac biomarkers. FAP familial amyloidotic
polyneuropathy; IV intravenous; mNIS+7 modified NIS+7; NCS nerve
conduction study; NIS Neuropathy Impairment ScoreEligibility
At screening, patients are 18–85 years old, with a diag-
nosis of hATTR amyloidosis, a documented TTR muta-
tion, and investigator-estimated survival of ≥2 years.
Eligible patients have an NIS of 5–130, polyneuropathy
disability (PND) score ≤IIIb, and adequate biochemical
liver function. The NIS range of 5–130 was selected to
include patients with disease sufficiently advanced to
show progression in the placebo group, but not so ad-
vanced as to preclude detection of a change in disease
status. Patients with previous OLT or sensorimotor/
autonomic neuropathy due to other known causes are
not included in the study. The key inclusion and exclu-
sion criteria are summarized in Table 1.Study design
Patients are randomized to receive either patisiran
0.3 mg/kg or placebo (normal saline 0.9%) once every
3 weeks for 18 months. Study drug is administered as an
intravenous infusion over 70 min (1 mL/min for the first
15 min, then 3 mL/min thereafter).
Patients have the option of discontinuing study drug if
they experience a protocol-defined rapid disease progres-
sion at 9 months, defined as ≥24-point increase in mNIS+7
from baseline (estimated 24-point increase in mNIS+7
score in the placebo group expected by 18 months based
on natural history study [47]), and FAP stage [7] progres-
sion relative to baseline, confirmed by an external adjudica-
tion committee. Such patients may receive alternative
therapy (local standard of care) and will be monitored
based on a modified visit schedule if they decide to stay on
study. All patients who complete the final 18-month assess-
ment are eligible to screen for an open-label extension
study of long-term patisiran treatment (NCT02510261).Premedication
To reduce the likelihood of infusion-related reactions,
patients are to receive the following premedications or
equivalent at least 60 min before each study drug
infusion: dexamethasone; oral acetaminophen/paraceta-
mol; an H2 blocker (e.g., ranitidine or famotidine); and
an H1 blocker (e.g., diphenhydramine).Concomitant medications
The use of tafamidis, diflunisal, doxycycline, taurourso-
deoxycholic acid, or any investigational agent other than
patisiran is prohibited during study participation. These
agents may have been used before screening, but a
wash-out period is mandated (14 days for tafamidis,
doxycycline, or tauroursodeoxycholic acid; 3 days for
diflunisal). Palliative and supportive-care medications
are permitted during the study.
Table 1 Key inclusion and exclusion criteria for the APOLLO study
Inclusion criteria Exclusion criteria
• Diagnosis of hATTR amyloidosis with documented mutation
• Anticipated survival ≥2 years
• Aged 18–85 years (inclusive)
• NIS of 5–130
• PND score ≤IIIb
• NCS sum of the sural SNAP, tibial CMAP, ulnar SNAP, ulnar
CMAP, and peroneal CMAP of ≥2 points
• Karnofsky performance status ≥60%
• Absolute neutrophil count ≥1500 cells/mm3
• Platelet count ≥50,000 cells/mm3
• Adequate biochemical liver functiona
• Serum creatinine ≤2 × ULN
• Previous liver transplantation, or liver transplantation planned during
study period
• Sensorimotor or autonomic neuropathy not related to hATTR amyloidosis
• Primary or leptomeningeal amyloidosis
• Type 1 diabetes
• Type 2 diabetes for ≥5 years
• Active hepatitis B or C, or HIV infection
• NYHA heart failure classification >2
• Acute coronary syndrome within past 3 months
• Uncontrolled cardiac arrhythmia or unstable angina
• Severe reaction to a liposomal product or hypersensitivity to oligonucleotides
• Unable to take premedications
• Received an investigational agent within 30 days/5 half-lives (whichever is
longer) of study drug administration
• Currently taking tafamidis, diflunisal, doxycycline, or tauroursodeoxycholic acid
CMAP compound muscle action potential; hATTR amyloidosis hereditary transthyretin-mediated amyloidosis; NCS nerve conduction study; NIS Neuropathy
Impairment Score; NYHA New York Heart Association; PND polyneuropathy disability; SNAP sensory nerve action potential; ULN upper limit of normal
aAspartate transaminase and alanine transaminase levels ≤2.5 × ULN; total bilirubin levels within normal limits; international normalized ratio ≤2.0
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Patients are randomized in a 2:1 (patisiran:placebo) ratio
using an interactive response system. Treatment arms are
balanced at study entry for: NIS (5–49 vs 50–130), early-
onset V30M disease (age < 50 years at onset) vs all other
mutations (including late-onset V30M), and previous use
of tafamidis or diflunisal. Patients and study personnel
who monitor patients during infusions and perform clin-
ical assessments are blinded to the study treatment. Un-
blinded personnel and pharmacists prepare the drug for
administration, but are not involved in patient manage-
ment or safety or efficacy assessments. Details of patients
who discontinue study drug at 9 months due to rapid dis-
ease progression remain blinded throughout the study.
Efficacy assessments
Primary outcome measure: mNIS+7
The primary objective is to determine the difference be-
tween the patisiran and placebo groups in change from
baseline in mNIS+7 at 18 months (Table 2). The mNIS+7
used in APOLLO has been modified from the original
NIS+7 to better characterize and quantify sensation all
over the body, autonomic function, and nerve conduction
changes associated with hATTR amyloidosis progression
[17]. A summary of the scoring components of the NIS+7
and mNIS+7 is provided in Table 3.
The mNIS+7 assessment tool [17] used in this study is
a 304-point composite measure of neurologic impair-
ment that includes: neurologic examination of lower
limbs, upper limbs, and cranial nerves (NIS-weakness
and reflexes); electrophysiologic measures of small and
large nerve fiber function (including nerve conduction
studies [NCS] Σ5 of ulnar, peroneal, and tibial com-
pound muscle action potential [CMAP] amplitudes and
sural and ulnar sensory nerve action potential [SNAP]
amplitudes; and smart somatotopic quantitative sensory
testing [S ST QSTing; including touch pressure and heatpain]) at defined body surface locations (Fig. 2); and
autonomic function (postural hypotension). Scoring for
NCS and postural hypotension is based on grading of
function: normal (<95th percentile) = 0 points; mildly
reduced (≥95th to <99th percentile) = 1 point; and very
reduced (≥99th percentile) = 2 points. The mNIS+7 is
measured in replicates during the pre-randomization
phase (at screening/baseline [21 days before the first
dose of study drug] and at baseline [≥24 h after screen-
ing/baseline measure]), and at 9 and 18 months. Two in-
dependent assessments are taken at each time point,
performed at least 24 h apart, but no greater than 7 days
apart. An increase in mNIS+7 score, or in any of its
components, indicates worsening impairment.
To standardize the efficacy assessment and minimize
variability across the multiple centers, neuromuscular
physicians were trained to perform the mNIS+7 evalu-
ation at a central center (Dyck Peripheral Nerve Re-
search Laboratory, Mayo Clinic, Rochester, MN, USA).
Secondary and exploratory clinical outcome measures
The secondary and exploratory objectives are to deter-
mine the effect of patisiran on a variety of clinical parame-
ters, based on their change from baseline to 18 months
(Table 2). Unless stated, parameters are assessed at screen-
ing/baseline, baseline, 9, and 18 months.
Neurologic and cardiac function
Neurologic function is measured using the NIS+7 tool [48]
based on two independent readings as described for mNIS
+7. For both mNIS+7 and NIS+7, the individual compo-
nents of the scores will be reported. Specific motor function
assessments include the timed 10-m walk test and hand
grip strength test (dynamometer), with measurements per-
formed on separate days. Cardiac function is assessed
through echocardiograms and cardiac biomarkers (troponin
I and N-terminal pro-brain-type natriuretic peptide).
Table 2 Study objectives
Objective
Primary • Determine the efficacy of patisiran by
evaluating the difference between the patisiran
and placebo groups in the change from
baseline of mNIS+7 at 18 months
Secondary
(hierarchical ordering)
• Norfolk Quality of Life-Diabetic Neuropathy
questionnaire
• NIS-weakness score
• Level of disability (Rasch-built Overall Disability
Scale)
• Timed 10-m walk test
• mBMIa
• Composite Autonomic Symptom Score
questionnaire
Exploratory • NIS + 7 score
• Grip strength
• EuroQol 5-Dimensions questionnaire
(EQ-5D-5L index, EQ VAS)
• Large versus small nerve fiber functionb
• Sensory and autonomic innervation and
analysis of nerve fiber density and sweat gland
nerve fiber density
• Dermal amyloid content on skin biopsy
• FAP stage and PND score
• Cardiac measures (echocardiogram, troponin I,
and NT-proBNP levels)
• Pharmacodynamic biomarkers
(TTR, RBP, and vitamin A)
• Proportion of patients with rapid disease
progression at 9 months
• Lower limb nerve injury via voluntary magnetic
resonance neurography
• Columbia-Suicide Severity Rating Scale (C-SSRS)
FAP familial amyloidotic polyneuropathy; mBMI modified body mass index;
mNIS modified Neuropathy Impairment Score; NIS Neuropathy Impairment
Score; NT-proBNP N-terminal pro-brain-type natriuretic peptide; PND
polyneuropathy disability; RBP retinol-binding protein; TTR transthyretin
amBMI calculated as kg/m2 × albumin (g/L)
bNerve fiber function assessed through nerve conduction studies of 5
attributes (Σ5): quantitative sensory testing by body surface area including
touch pressure and heat pain, vibration detection threshold, heart rate
response to deep breathing, and postural blood pressure
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QoL assessments include the Norfolk QOL-DN question-
naire [49], a 35-item measure sensitive to small fiber, large
fiber, and autonomic nerve function, which has been
shown to be a reliable indicator of disease severity in
patients with hATTR amyloidosis [20] (increase in
score = worsening QoL), and the EQ-5D™ questionnaire
[50] (decrease in score = worsening QoL). Autonomic
symptoms are evaluated using the 31-question Composite
Autonomic Symptom Score (COMPASS)-31 question-
naire, which covers six autonomic domains (orthostatic
intolerance, vasomotor, secretomotor, gastrointestinal,
bladder, and pupillomotor) [51] (increase in score = wors-
ening symptoms). Activity and social function are assessed
through the Rasch-built Overall Disability Scale (R-ODS),
a 24-item scale to capture limitations on everyday activ-
ities [52] (decrease in score = worsening disability). Nutri-
tional status is gauged using mBMI (kg/m2 × albumin [g/
L]), taken at baseline, and days 84, 189, 357, 462, and 546(18-month assessment). Changes in ambulation are
assessed according to FAP stage [7] and PND score [53]
(increase in stage/score = worsening impairment), and the
timed 10-m walk test (increase in duration = worsening
impairment). Lower limb nerve injury is serially evaluated
via voluntary magnetic resonance neurography approxi-
mately every 6 months in patients providing voluntary
consent.Pathologic nerve fiber and amyloid evaluation
Nerve fibers and amyloid deposits in the skin are quanti-
fied through measurement of intraepidermal nerve fiber
density, sweat gland nerve fiber density, and dermal
amyloid burden using tandem 3 mm skin punch biopsies
in patients providing voluntary consent. At each time
point, one set of biopsies is taken from the lower leg and
another from the distal thigh.Pharmacodynamic assessments
Levels of serum TTR protein, vitamin A, and retinol-
binding protein (RBP) are measured at baseline, pre-dose
on day 0, and on days 21, 126, 252, 253–272 (9 months),
273, 399, 546, and 553–560 (18 months). Serum TTR is
measured using an enzyme-linked immunosorbent assay
and a turbidimetric assay. Serum RBP is quantified using
nephelometry. Serum samples are evaluated by a high-
performance liquid chromatography assay to determine
vitamin A levels. Pharmacodynamic samples are not taken
at 18 months for patients who discontinue treatment at
9 months (modified schedule).Pharmacokinetic assessments
Plasma samples for pharmacokinetic analysis are taken pre-
dose and post-dose on days 0, 21, 126, 252, 399, and 546.
Pharmacokinetic parameters for plasma siRNA are evalu-
ated using a validated ATTO™-probe high-performance
liquid chromatography assay.Safety assessments
Adverse events (AEs) are assessed throughout the study,
and reported according to the Medical Dictionary of
Regulatory Activities (version 18.0 or later). AEs are
graded based on their severity (mild, moderate, or
severe) and the causal relationship to study drug or pre-
medication recorded. Clinical laboratory and chemistry
tests, thyroid function parameters, urinalysis, anti-drug
antibodies, electrocardiograms, physical and vital signs,
and ophthalmology examinations (including electroreti-
nography) are also monitored. The Columbia-Suicide
Severity Rating Scale (C-SSRS) is used to assess mental
status as it relates to suicidal ideation and behavior.
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Fig. 2 Schematic representation of smart QSTing of body sites. Smart testing uses defined and quantitated stimuli of touch pressure and heat as
pain using validated computer software, standard conditions, and previously obtained reference values from the assessment of healthy-subject
cohorts. Dots indicate testing site. HP5, heat as pain 5 (graded 1–10); mNIS+7 modified NIS+7; NIS Neuropathy Impairment Score; S ST QSTing
Smart Somatotopic Quantitative Sensory Testing; TP touch pressure [17, 62]
Adams et al. BMC Neurology  (2017) 17:181 Page 7 of 12Statistical analyses
A sample size of approximately 200 patients will provide
90% power to test a treatment difference of 8.95 points
(37.5%) in mNIS+7 change from baseline (primary end-
point) with a two-sided α = 0.05. The sample size of ap-
proximately 200 is based on an assumed premature
discontinuation rate of 25%.
The populations analyzed in the study are: the modi-
fied intent-to-treat (mITT) population (all patients who
were randomized and received at least one dose of study
drug); the per-protocol population (all patients who
completed all efficacy assessments and did not have any
major protocol violations); and the safety population
(all patients who received at least one dose of study
drug).
The analysis of efficacy endpoints will be conducted
for the mITT population. Formal statistical hypothesis
testing will be performed on the primary and secondary
efficacy endpoints with all tests conducted at the nom-
inal two-sided, 0.05 level of significance.
Discussion
The APOLLO study examines the efficacy and safety of
the investigational RNAi therapeutic patisiran in a broad
hATTR amyloidosis population, including patients with
any amyloidogenic TTR mutation and with a wide range
of neuropathy severity and age at baseline. The compos-
ite primary endpoint of APOLLO (mNIS+7) is well
suited for use in hATTR amyloidosis because it encom-
passes multiple aspects of the polyneuropathy and can
capture changes during disease progression. In addition,QoL, motor function, health status, autonomic symp-
toms, cardiac assessments, and everyday functioning
are included as secondary or exploratory endpoints to
assess the impact of patisiran on a range of disease
involvement.
The mNIS+7 used to assess neurologic impairment in
this study is more robust and comprehensive than the
tools used in the trials of tafamidis (NIS-LL) [19] or
diflunisal (NIS+7) [24], with the modifications outlined
in Table 3. One of the key attributes of the mNIS+7 ver-
sus NIS+7 is the measurement of sensation, with S ST
QSTing used in preference to NIS-sensation evaluation
and vibration detection threshold. Indeed, the NIS-
sensation score is not included in mNIS+7 in APOLLO,
as the study of Suanprasert et al. in 97 patients with
hATTR amyloidosis suggested that this score did not ad-
equately capture sensation loss [17]. Compared with
NIS-sensation, S ST QSTing provides an improved bal-
ance between large and small sensory nerve fibers and
measures sensation loss over the whole body rather than
at distal sites such as big toes and fingers. Whilst S ST
QSTing is time-consuming and requires specialist train-
ing and standardized protocols to avoid procedural vari-
ability [54, 55], these demands are necessary to assess
sensation loss somatopically and accurately [56]. Aside
from sensation, the other major alteration from the NIS+7
is in the measurement of nerve conduction. Here, the com-
bined NCSΣ5 in the mNIS+7 includes only action potential
amplitudes, which are more suited to capture changes in
disease course for hATTR amyloidosis as this disease has a
primarily axonal pathophysiology. A further change from
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hypotension was included because heart rate decrease
with deep breathing was considered an inconsistent
assessment of autonomic function as it is unevaluable
in patients with cardiac pacemakers and frequently
unevaluable in patients with arrhythmias [17, 56]. It
is recognized however, that pharmacologic interven-
tions (e.g., fludrocortisone and midodrine) can be
used to treat postural hypotension [57], and the use
of any such strategies should be considered when
gauging the effect of patisiran on this measure. With
the modifications to the NIS+7, the total score was
increased to 304 points for the mNIS+7 used in this
study. Measurement of muscle weakness and stretch re-
flexes were considered adequate with the original NIS+7,
so these elements have not been modified [17].
However, it should be noted that the mNIS+7 de-
scribed by Suanprasert et al., which is used in APOLLO,
is different from that currently being used in the study
investigating the anti-TTR antisense oligonucleotide
IONIS-TTRRx (mNIS+7Ionis). The critical difference be-
tween these two versions of the mNIS+7 is in the meas-
urement of sensation: mNIS+7Ionis includes the NIS-
sensation testing score from the original NIS+7, in
addition to S ST QSTing [56] (Table 3). As discussed,
NIS-sensation may not provide a true reflection of sen-
sation impairment, with inclusion of the original NIS+7-
sensation testing potentially being redundant. Indeed,
this may lead to double counting for assessments of sen-
sation. The other notable difference is that the mNIS+7Ionis
does not include postural hypotension, and instead retains
the heart rate decrease with deep breathing measure of the
NIS+7 for assessment of autonomic function, which has
the limitations discussed above for patients with pace-
makers or cardiac arrhythmias. Both mNIS+7 and
mNIS+7Ionis include only CMAPs and SNAPs as
nerve conduction measures (Table 3). Regarding as-
sessment of NCS, it is worth noting that these are
expressed as normal deviates in the mNIS+7Ionis,
whereas they are graded by defined categories in
mNIS+7 (Table 3).
The features of the mNIS+7 described above have
been introduced to create a tool suitable for use in
hATTR amyloidosis clinical studies. As assessment of
neuropathic measures is subject to variability between
investigators, extensive training is provided to support
the use of a standardized and validated methodology
and ensure that scoring is consistent and accurate. Spe-
cifically, specialized training is provided for neuromus-
cular physicians, with certification upon completion. For
clinical assessment of neuropathy signs and symptoms,
neuromuscular experts are trained to use only unequivo-
cal abnormalities (accounting for age, sex, physical fit-
ness, and anthropomorphic variables) rather than moretraditional clinical criteria, and not to grade for con-
comitant neuromuscular disease. Previous analyses have
shown that this strategy, when used by trained special-
ists, leads to increased reproducibility and a notable
improvement in proficiency when scoring clinical mea-
sures, such as weakness and reflexes, as used in
APOLLO [58, 59]. Variability between centers has
also been noted for NCS, which is countered in this
study through specialist training on techniques and
reference values, and evaluation of tracings at a cen-
tral reading center; these methodologies have been
shown to reduce inter-investigator variability [60, 61]. Of
the other mNIS+7 measures, the S ST QSTings used in
APOLLO are also standardized and referenced, to ensure
generation of accurate and comparable data across the
study [62].
The clinical relevance of NIS has been previously dem-
onstrated, with total NIS correlated with FAP stage,
PND score, and QoL (Norfolk QOL-DN and SF-36) in
patients with hATTR amyloidosis [47, 56]. In addition,
rapid worsening of NIS was observed in untreated pa-
tients in a natural history study of patients with hATTR
amyloidosis [47], fitting with the relentless progression
expected for this disease [8]. The estimated rate of NIS
progression for a patient with a baseline NIS of 32 was
14.3 points per year [47], and a separate analysis has in-
dicated a worsening in NIS-LL of up to 7.4 points over
12 months in patients with a baseline NIS-LL of 20–30
[63]. The rapid neurologic deterioration observed in pa-
tients with hATTR amyloidosis contrasts with lower
rates of NIS progression seen in other neuropathies
[64, 65]. For example, in patients with mild-to-moderate
diabetic distal symmetric sensorimotor polyneuropathy,
NIS and NIS-LL increased by only 0.61 and 0.43 points,
respectively, over 4 years of placebo treatment [64]. Fur-
thermore, a study of disease progression in Charcot–
Marie–Tooth disease type 1A reported an annual NIS
increase of 1.37 points [65].
Based on the described modifications to the NIS, it is
anticipated that the mNIS+7 will more accurately cap-
ture the degree of polyneuropathy and neurologic im-
pairment in patients with hATTR amyloidosis. Indeed,
rapid disease progression in untreated patients has also
been demonstrated using the mNIS+7, with an increase
of approximately 24 points anticipated after 18 months
[47]. The clinical value of the mNIS+7 was further dem-
onstrated in recent analyses of the baseline data from
APOLLO, which showed an association between mNIS+7
and FAP stage and PND score (Fig. 3). In addition, investi-
gation of the mNIS+7Ionis showed that clinical polyneur-
opathy signs and symptoms correlated strongly with
assessments of action potential amplitudes and soma-
totopic touch pressure [56], which are also included
in the mNIS+7. Of the other measures taken in
Fig. 3 Association between mNIS+7 and (A) FAP stage and (B) PND score using baseline data from the APOLLO study (n = 225). FAP familial
amyloidotic polyneuropathy; mNIS+7 modified Neuropathy Impairment Score +7; PND polyneuropathy disability
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knockdown was demonstrated in the Phase 2 open-
label extension study of patisiran [66], supporting the
hypothesis that reducing levels of amyloidogenic pro-
tein leads to clinical benefit in hATTR amyloidosis
(e.g., via OLT [28]).
hATTR amyloidosis is associated with symptoms
across multiple systems [2, 67]. In addition to the neuro-
logic symptoms, patients often present with a mixed
phenotype including concurrent cardiac symptoms. Car-
diomyopathy associated with hATTR amyloidosis can
lead to heart failure and death, highlighting the need for
vigilance around cardiac amyloid fibril accumulation.
The APOLLO study therefore includes echocardio-
graphic and biochemical cardiac parameters to assess
the impact of patisiran on cardiac progression.
The impact of the diverse disease symptoms may not
be fully captured by clinical and laboratory examina-
tions, so QoL measures were included as key endpoints
in the studies of tafamidis and diflunisal [19, 24].
APOLLO uses the Norfolk QOL-DN and EQ-5D ques-
tionnaires to assess QoL. The Norfolk QOL-DN ques-
tionnaire evaluates small and large nerve fiber function
in addition to autonomic impairment and activities of
daily living. It has demonstrated utility in patients with
hATTR amyloidosis with polyneuropathy both as a
measure of disease severity and as a clinical endpoint to
assess response to treatment [20, 21]. The EQ-5D ques-
tionnaire has been used as part of the international
Transthyretin Amyloidosis Outcomes Survey (THAOS),
which demonstrated worsening QoL with disease pro-
gression [22]. Autonomic symptoms, particularly gastro-
intestinal events, are common in patients with hATTR
amyloidosis [23] underpinning the comprehensive
assessment of autonomic function using the COMPASS-
31 questionnaire [51]. Other measures in APOLLO
include the R-ODS survey [52] for assessment of the ef-
fects of patisiran on activities of daily living. The R-ODShas already been used to demonstrate that hATTR amyl-
oidosis can affect activities such as washing dishes or
fastening buttons [68], and has been validated in patients
with V30M hATTR amyloidosis [69].
The pharmacotherapies currently approved or avail-
able for hATTR amyloidosis can slow or sometimes
stabilize disease, but there is little evidence that
complete stabilization or reversal of nerve damage can
be achieved. Sensory and autonomic innervation in skin
punch biopsies are being evaluated in APOLLO to deter-
mine whether patisiran can increase nerve fiber density.
Increases in sweat gland fiber density were observed in
the Phase 2 open-label extension study of patisiran [46],
and APOLLO will provide an opportunity for these find-
ings to be validated in a placebo-controlled setting. Of
interest, sweat gland nerve fiber density has previously
been associated with ambulation in patients with hATTR
amyloidosis [70]. In addition to nerve fiber density, these
skin biopsies are also being evaluated in both the Phase
2 open-label extension study and APOLLO for changes
in dermal amyloid burden.
Aside from clinical endpoints related to efficacy, safety
and pharmacodynamics will also be assessed throughout
the APOLLO study and subsequent open-label exten-
sion. Longer-term data from the Phase 2 open-label
extension study suggest patisiran is well tolerated, but
APOLLO will allow comparison against a placebo-
controlled arm. In particular, the safety of prolonged
lowering of vitamin A levels, associated with TTR reduc-
tion, will be assessed. TTR reduction itself provides a
convenient biomarker to assess patisiran activity, and
reduction in the pathogenic protein may also relate to
clinical parameters.
Recruitment for APOLLO started in December 2013
and was completed in January 2016, with 225 patients en-
rolled. This trial represents the largest Phase 3 study of an
RNAi strategy for the treatment of hATTR amyloidosis,
with clinical endpoints that strive to assess the multiple
Adams et al. BMC Neurology  (2017) 17:181 Page 10 of 12ways in which this disease affects patient well-being and
function. The Patisiran Global open-label extension study
was initiated in July 2015, and will provide further data on
long-term safety and efficacy of patisiran in patients with
hATTR amyloidosis.
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